BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Mid Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Glenmark Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Glenmark Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 12.4% | 18.5% | 20.5% | 14.8% | 16.5% | 14% | 15.3% | 14.2% | 4.4% | 4.9% | - |
| Value Creation Index ⓘ | -0.1 | 0.7 | 0.8 | 0.1 | 0.2 | 0.0 | 0.1 | 0.1 | -0.7 | -0.6 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 6,681 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 12,100 |
| Sales YoY Gr. | - | 13.2% | 20.1% | -0.1% | 8.7% | 7.9% | 2.9% | 12.4% | -5.9% | 2% | - |
| Adj EPS ⓘ | 12.6 | 26.7 | 43 | 26.8 | 24.2 | 23.3 | 35.1 | 37.8 | 7.8 | -45 | -31 |
| YoY Gr. | - | 113% | 60.7% | -37.6% | -9.7% | -3.8% | 50.8% | 7.7% | -79.4% | -677.4% | - |
| BVPS (₹) ⓘ | 65.7 | 128.6 | 159.2 | 182.6 | 198.3 | 214.7 | 249.6 | 321.5 | 335.1 | 277.5 | 299.3 |
| Adj Net Profit ⓘ | 341 | 754 | 1,212 | 757 | 683 | 657 | 991 | 1,067 | 220 | -1,269 | -875 |
| Cash Flow from Ops. ⓘ | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | - |
| Debt/CF from Ops. ⓘ | 7.9 | 11.6 | 7.2 | 2.8 | 3.4 | 3.5 | 4.1 | 3.3 | 7 | -3.7 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 6.5% | 3.7% | 2.6% | 2% | ||||
| Adj EPS ⓘ | -215.2% | -213.2% | -208.6% | -677.4% | ||||
| BVPSⓘ | 17.4% | 7% | 3.6% | -17.2% | ||||
| Share Price | 6.1% | 33.9% | 42% | 91% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.3 | 27.9 | 29.9 | 15.7 | 12.7 | 11.3 | 15.1 | 13.2 | 2.4 | -14.7 | -10.8 |
| Op. Profit Mgn % ⓘ | 18.2 | 19.2 | 23.2 | 17.8 | 16.1 | 16 | 19.7 | 18.9 | 14.1 | 10.1 | 12.3 |
| Net Profit Mgn % ⓘ | 5.1 | 10 | 13.4 | 8.3 | 6.9 | 6.2 | 9.1 | 9.1 | 2.6 | -10.2 | -7.2 |
| Debt to Equity ⓘ | 2.1 | 1.1 | 1.1 | 0.9 | 0.8 | 0.8 | 0.7 | 0.4 | 0.5 | 0.1 | 0 |
| Working Cap Days ⓘ | 244 | 242 | 219 | 236 | 217 | 201 | 88 | 88 | 94 | 88 | 115 |
| Cash Conv. Cycle ⓘ | 77 | 60 | 69 | 82 | 66 | 56 | -28 | -21 | -4 | -14 | 31 |
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years 2.58%
Sales growth is not so good in last 4 quarters at -0.66%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 199.9 | -31 |
| TTM Sales (₹ Cr.) | 8,273 | 12,100 |
| BVPS (₹.) ⓘ | 848.6 | 299.3 |
| Reserves (₹ Cr.) ⓘ | 23,918 | 8,417 |
| P/BV ⓘ | 1.74 | 4.95 |
| PE ⓘ | 7.40 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 761.15 / 1830.05 |
| All Time Low / High (₹) | 1.89 / 1830.05 |
| Market Cap (₹ Cr.) | 41,778 |
| Equity (₹ Cr.) | 28.2 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 43.4 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,681 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 |
| Operating Expenses ⓘ | 5,467 | 6,125 | 7,043 | 7,459 | 8,280 | 8,943 | 8,860 | 9,985 | 9,948 | 10,618 |
| Manufacturing Costs | 927 | 624 | 674 | 786 | 890 | 843 | 803 | 985 | 745 | 937 |
| Material Costs | 1,538 | 2,247 | 2,552 | 2,963 | 3,284 | 3,624 | 3,620 | 4,312 | 4,204 | 4,352 |
| Employee Cost | 1,213 | 1,378 | 1,641 | 1,872 | 2,056 | 2,255 | 2,344 | 2,447 | 2,601 | 2,868 |
| Other Costs ⓘ | 1,788 | 1,876 | 2,176 | 1,838 | 2,049 | 2,221 | 2,092 | 2,240 | 2,398 | 2,460 |
| Operating Profit ⓘ | 1,214 | 1,437 | 2,037 | 1,615 | 1,586 | 1,698 | 2,084 | 2,320 | 1,635 | 1,195 |
| Operating Profit Margin (%) | 18.2% | 19.0% | 22.4% | 17.8% | 16.1% | 16.0% | 19.0% | 18.9% | 14.1% | 10.1% |
| Other Income ⓘ | 7 | 20 | 37 | 91 | 208 | 160 | 50 | 167 | 289 | 840 |
| Interest ⓘ | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 |
| Depreciation ⓘ | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 |
| Exceptional Items ⓘ | -187 | 0 | -81 | 0 | 167 | 33 | 45 | -261 | -766 | -901 |
| Profit Before Tax ⓘ | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 240 | 36 |
| Tax ⓘ | 334 | 301 | 383 | 315 | 376 | 320 | 412 | 448 | 329 | 1,867 |
| Profit After Tax | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | -90 | -1,831 |
| PAT Margin (%) | 3.1% | 9.8% | 12.2% | 8.9% | 9.4% | 7.3% | 8.9% | 8.1% | -0.8% | -15.5% |
| Adjusted EPS (₹) | 7.7 | 26.3 | 39.3 | 28.5 | 32.8 | 27.5 | 34.4 | 33.4 | 10.5 | -53.2 |
| Dividend Payout Ratio (%) | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 1,783 | 3,628 | 4,491 | 5,153 | 5,595 | 6,057 | 7,043 | 9,070 | 9,456 | 7,830 |
| Share Capital ⓘ | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves ⓘ | 1,756 | 3,600 | 4,463 | 5,125 | 5,566 | 6,029 | 7,015 | 9,042 | 9,428 | 7,801 |
| Minority Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 351 | 365 | -0 |
| Debt | 2,922 | 3,275 | 4,724 | 4,437 | 3,877 | 4,486 | 4,402 | 2,942 | 4,202 | 833 |
| Long Term Debt | 2,574 | 2,487 | 4,536 | 4,142 | 3,574 | 4,043 | 3,889 | 2,572 | 3,852 | 0 |
| Short Term Debt | 348 | 787 | 187 | 295 | 303 | 443 | 513 | 370 | 350 | 833 |
| Trade Payables | 1,948 | 1,941 | 1,743 | 1,870 | 2,221 | 2,126 | 2,238 | 2,289 | 2,000 | 2,536 |
| Others Liabilities ⓘ | 1,656 | 285 | -505 | -184 | 214 | 561 | 387 | 745 | 1,542 | 2,110 |
| Total Liabilities ⓘ | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 | 13,309 |
Fixed Assets | ||||||||||
| Gross Block | 3,495 | 4,301 | 4,770 | 5,368 | 6,527 | 8,270 | 8,732 | 10,213 | 10,360 | 9,620 |
| Accumulated Depreciation | 1,480 | 1,707 | 2,015 | 2,338 | 2,857 | 3,241 | 3,603 | 4,326 | 4,938 | 5,409 |
| Net Fixed Assetsⓘ | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 |
| CWIP ⓘ | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 |
| Investmentsⓘ | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 |
| Inventories | 1,269 | 1,568 | 2,139 | 2,031 | 2,252 | 2,136 | 2,277 | 2,500 | 2,374 | 2,513 |
| Trade Receivables | 2,512 | 2,493 | 2,404 | 2,332 | 2,195 | 2,409 | 2,572 | 3,101 | 3,665 | 1,858 |
| Cash Equivalents | 776 | 857 | 1,058 | 1,235 | 938 | 1,111 | 1,139 | 1,412 | 1,160 | 1,659 |
| Others Assetsⓘ | 1,243 | 1,057 | 1,373 | 1,512 | 1,423 | 1,298 | 1,546 | 1,438 | 3,711 | 1,616 |
| Total Assets ⓘ | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 17,566 | 13,309 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 |
| PBT ⓘ | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 569 |
| Adjustment ⓘ | 523 | 391 | 727 | 571 | 330 | 636 | 645 | 787 | 1,472 | 1,010 |
| Changes in Working Capital ⓘ | -267 | -612 | -862 | 309 | 136 | 127 | -386 | -561 | -1074 | -797 |
| Tax Paid ⓘ | -318 | -478 | -699 | -352 | -443 | -467 | -510 | -558 | -641 | -1,047 |
| Cash Flow From Investing Activity ⓘ | -540 | -880 | -712 | -1,013 | -699 | -784 | -675 | -333 | -528 | 4,561 |
| Capex | -538 | -889 | -733 | -1,023 | -610 | -775 | -675 | -358 | -551 | -896 |
| Net Investments | 0 | 0 | 0 | 0 | -15 | 5 | 0 | -10 | -1 | 7 |
| Others ⓘ | -2 | 8 | 21 | 9 | -74 | -13 | 0 | 35 | 23 | 5,450 |
| Cash Flow From Financing Activityⓘ | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 |
| Net Proceeds from Shares ⓘ | 2 | 935 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 478 | -441 | 1,400 | -290 | -381 | -116 | -67 | -889 | 650 | -3,649 |
| Interest Paid ⓘ | -179 | -180 | -184 | -213 | -270 | -301 | -294 | -251 | -312 | -517 |
| Dividend Paid ⓘ | -54 | -68 | -68 | -68 | -68 | -69 | -70 | -93 | -137 | -118 |
| Others ⓘ | -47 | 452 | -606 | 102 | -20 | 41 | -11 | 712 | -279 | 378 |
| Net Cash Flow ⓘ | 141 | 163 | 488 | 166 | -114 | 164 | 14 | 255 | 19 | 389 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.79 | 27.46 | 27.31 | 16.67 | 17.21 | 13.32 | 14.81 | 12.33 | -0.97 | -21.18 |
| ROCE (%) | 12.4 | 18.53 | 20.54 | 14.77 | 16.47 | 14.04 | 15.3 | 14.19 | 4.43 | 4.88 |
| Asset Turnover Ratio | 0.83 | 0.88 | 0.94 | 0.84 | 0.85 | 0.85 | 1.85 | 1.89 | 1.71 | 1.79 |
| PAT to CFO Conversion(x) | 2.31 | 0.46 | 0.59 | 2.05 | 1.43 | 1.79 | 1.17 | 1.12 | N/A | N/A | Working Capital Days |
| Receivable Days | 126 | 119 | 97 | 95 | 84 | 79 | 36 | 37 | 44 | 36 |
| Inventory Days | 59 | 68 | 74 | 84 | 79 | 75 | 32 | 31 | 32 | 32 |
| Payable Days | 354 | 310 | 263 | 222 | 227 | 219 | 220 | 192 | 186 | 190 |
Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.
India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.
Business area of the company
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.
Awards
Milestone
2010
2012
2014
2015
2016
2019
2020
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
